Press Releases

Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London

Panthera’s clinical trial sites are helping to evaluate an alternative AstraZeneca vaccine for people who are unable to have the currently approved Covid-19 vaccines. The treatment is aimed at helping those people with a compromised immune system, who cannot be vaccinated, vaccine hesitant and those who are unlikely to respond to a vaccination.

IntegrateRNA Provided Innovative mRNA Solutions for Research of Life Sciences, Clinical and Drug Development

Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics

BOC Sciences Upgrades Impurity Isolation and Identification Service to Help Advance Drug Research

Profacgen Provides Comprehensive Solutions for PEGylation

 Protheragen Offers Acquisition Opportunity for A Complete Pentapeptide Library

Data Analysis at AI & Medicine: PrediXcan Based Analysis and BSLMM Prediction

AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease

AMZELL B.V to initiate a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

BioIVT Announces Charitable Donations to Honor its Clients’ Commitment to Medical Research

BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity.

Cytel Acquires HEOR Experts Purple Squirrel Economics

Cytel has today announced the acquisition of Purple Squirrel Economics, expanding Cytel’s distinguished real world and advanced analytics team and further growing the global reach of Cytel’s extensive Health Economics Outcomes Research (HEOR) expertise. The acquisition marks the latest step in Cytel’s commitment to continue powering pharmaceutical development through novel applications of modern data analytics, and follows the company’s recent acquisitions of both MTEK Sciences and Ingress Health in the past year. Based in the US and Canada, Purple Squirrel Economics offers strategic leadership with a global perspective by engaging a team of senior health economists, HEOR value communication writers, research analysts, and market access professionals trusted by both regulators and payers. They help companies prove product value with rigorous quantitative insights, thereby driving products towards commercial success.

CCT Research Expands Clinical Trial Capabilities to Salt Lake City

CCT Research involved in COVID-19 vaccine research expands to Utah, partnering with local physician practices to enhance trial participation.

McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module. Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and allows patients and sites to choose how they want to participate in the study — smartphone, tablet, or web. Lunexis ePRO+ allows sites and patients to have unprecedented flexibility to choose the technology option that makes the most sense for them.

Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy

Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda®, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer

Cerner and Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes

Cerner Corporation (NASDAQ: CERN), a global health care technology company, today announced an investment in Elligo Health Research, a leading integrated research organization that enables clinical trials with nationwide community-based health care practices.

APIS Assay Technologies Ltd. and Moffitt Cancer Center sign Master Collaboration Agreement on TROLL Biomarker assessment

APIS Assay Technologies has announced a master collaboration agreement with Moffitt Cancer Centre to characterise the suitability of TROLL-2 and TROLL-3 as predictive biomarkers of cancer progression with the goal to assess the role of TROLLs as markers of response to chemotherapy. The research collaboration will aim to determine the feasibility of lncRNAs as a diagnostic tool for the prediction of efficacy of treatment pathways and prognosis of treatment outcome in chemoresistant TNBCs and further analysing NSCLC and melanoma as potential diagnostic targets for the TROLL Biomarkers.

Alpha Solway honours top doctor with new ‘People’s Choice’ award

Scottish kidney specialist named winner at Scottish Health Awards for crucial work during coronavirus outbreak.

Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

iCAD ProFound AI for 3D Mammography and ProFound AI Risk will be deployed to 100 percent of Solis Mammography’s installed base, a majority of which are Hologic systems. The agreement is not exclusive. The agreement underscores promise of shifting mammography from age-based screening paradigm to a risk-adjusted precision screening paradigm personalized for every woman. ProFound AI, which aids in the detection of breast cancer in 3D mammography, or digital breast tomosynthesis (DBT), became the first software of its kind to be FDA-cleared in December 2018. The technology rapidly and accurately analyzes each DBT image, or slice, and provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. *Delivers clinically proven improvements in sensitivity, specificity, time-savings and recall rates. This leads to earlier breast cancer detection and reduced rate of false positive *ProFound AI Risk is the only commercially available risk assessment solution to provide a short term vs. long term risk of developing breast cancer based solely on a screening mammogram. *ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets.

Medovate announces new agreement with Mercury Medical® securing 100% distributor coverage for SAFIRA™ in the USA

https://news.lifesciencenewswire.com/newsroom/medovate-announces-new-agreement-with-mercury-medical-securing-100-distributor-coverage-for-safira-in-the-usa

ENPICOM and MiLaboratories join forces to power better Repertoire Sequencing data management and analysis workflows

ENPICOM BV, an innovative bioinformatics software engineering company, has announced a strategic partnership with MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, to enhance Repertoire Sequencing data management and analysis workflows. The collaboration provides a software solution within a single platform, by combining MiLaboratories's MiXCR and ENPICOM’s cloud-based IGX Platform, allows users to choose their preferred profiling solution, leverage its intuitive user interface and unique data management capabilities.

New Study Confirms VisualDx’s AI Improves Diagnostic Accuracy at the Point of Care

A new study reveals that VisualDx's artificial intelligence solution identifies skin conditions with 68% accuracy across all skin types.